Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Feasibility Trial of a Culturally Tailored Resilience Intervention for Underserved Breast Cancer Survivors (BRIGHT)

5 novembre 2026 mis à jour par: Sinem Uzar Ozcetin, University College Dublin

BRIGHT (Breast Cancer Resilience Intervention for Growth, Hope and Thriving): Co-Designing and Feasibility Testing a Culturally Tailored Resilience Intervention for Underserved Breast Cancer Survivors in Ireland

The goal of this feasibility trial is to find out whether a culturally tailored resilience intervention, called BRIGHT, can be delivered and tested with breast cancer survivors from underserved communities in Ireland. These include women from minority ethnic groups (including Travellers), migrant women, women living in rural areas and women experiencing socioeconomic disadvantage.

The main questions it aims to answer are:

  • Can enough women be recruited and kept in the study?
  • Do women attend the sessions and find the intervention acceptable?
  • Can facilitators deliver the intervention as planned? Researchers will compare the BRIGHT resilience intervention with usual survivorship care plus a resource booklet. The results will show whether a larger, definitive trial is possible and will give early signals of benefit for psychological distress, fear of cancer recurrence, resilience, quality of life and unmet supportive care needs.

Participants will:

  • Be randomly assigned to the BRIGHT resilience intervention or to usual care plus the BRIGHT Survivorship Resource Booklet
  • In the BRIGHT group, attend 8 weekly 90-minute facilitated group sessions, in the community or online
  • Complete questionnaires at the start, after 8 weeks and 3 months after the programme ends
  • Be invited to take part in an interview about their experience (some participants only) Women in the usual care group will be offered the BRIGHT programme after their final follow-up.

Aperçu de l'étude

Description détaillée

Background: Women from underserved communities in Ireland often experience higher psychological distress, fear of cancer recurrence, unmet supportive care needs and barriers to survivorship services. Few psychosocial survivorship interventions have been designed or culturally adapted for these groups.

Intervention development: The BRIGHT resilience intervention is being developed in earlier stages of Project BRIGHT, a 42-month mixed methods study submitted for funding to Breast Cancer Now. These stages include a national survey of breast cancer survivors, interviews with women from underserved communities and a structured co-design process with survivors, clinicians, researchers and community stakeholders. Cultural adaptation is guided by Resnicow's Cultural Adaptation Framework and documented using FRAME.

Intervention: An 8-week hybrid programme of weekly 90-minute facilitated group sessions, delivered face to face in the community and through secure online sessions, with a participant workbook. Planned modules, subject to the co-design findings, are psychoeducation; emotional adjustment; managing fear of recurrence; culturally responsive coping and resilience; self-advocacy; healthcare navigation; peer support; and signposting to community resources. Materials will be translated into 2 to 3 priority languages.

Design: A two-arm parallel feasibility randomised controlled trial with 80 participants, individually randomised 1:1. A computer-generated, concealed allocation sequence will be managed by an independent researcher not involved in recruitment or intervention delivery. The comparator is usual survivorship care plus the BRIGHT Survivorship Resource Booklet, with delayed access to the BRIGHT programme after the 3-month follow-up (waitlist crossover). Allowing for up to 25% attrition, at least 60 participants are expected to be evaluable at final follow-up.

Data collection: Questionnaires at baseline (T0), after the intervention (T1, Week 8) and 3 months after the intervention (T2).

Progression criteria: Progression to a definitive trial will be guided by pre-specified traffic light criteria: at least 80% retention, at least 75% session completion, at least 85% intervention fidelity and a recruitment rate of at least 4 participants per site per month.

Process evaluation: Guided by the MRC Process Evaluation Framework, semi-structured interviews with 15 to 20 participants and facilitators will explore acceptability, barriers and facilitators to implementation, mechanisms of impact, fidelity and context. Fidelity will be assessed using facilitator session checklists, attendance records and independent review of a sample of recorded sessions.

Analysis: Feasibility outcomes will be reported using descriptive statistics with 95% confidence intervals. Exploratory analyses of secondary outcomes will estimate effect sizes and variance to inform the sample size for a future definitive trial.

Type d'étude

Interventionnel

Inscription (Estimé)

80

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Femelle

La description

Inclusion Criteria:

  • Women aged 18 years or older.
  • Diagnosis of breast cancer stage 0 to III.
  • Completed primary treatment (surgery, chemotherapy and/or radiotherapy)
  • Belong to at least one underserved group: minority ethnic group (including Irish Travellers), migrant or refugee, living in a rural area, or experiencing socioeconomic disadvantage.
  • Living in Ireland
  • Able to give informed consent, with interpreter support if needed
  • Able to attend group sessions face to face or online

Exclusion Criteria:

  • Metastatic (stage IV) breast cancer
  • Severe mental health or cognitive difficulties that would prevent taking part in group sessions.
  • Currently taking part in another psychosocial intervention study
  • Took part in the BRIGHT co-design panel or user testing

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Soins de soutien
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: BRIGHT Resilience Intervention

Participants attend the 8-week culturally tailored BRIGHT resilience intervention: weekly 90-minute

A culturally tailored, co-designed group resilience programme for breast cancer survivors from underserved communities. Eight weekly 90-minute facilitated sessions, delivered in a hybrid format (community face to face and secure online). Planned modules: psychoeducation; emotional adjustment; managing fear of recurrence; culturally responsive coping and resilience; self-advocacy; healthcare navigation; peer support; and signposting to community resources. Delivered by trained facilitators using a standardised manual. Materials available in English and 2 to 3 priority languages.

Comparateur actif: Enhanced Usual Care

Participants receive standard oncology survivorship care plus the BRIGHT Survivorship Resource Booklet. They are offered the BRIGHT resilience intervention after the 3-month follow-up (waitlist crossover).

BRIGHT Survivorship Resource Booklet A printed resource booklet with survivorship information and signposting to support services, given alongside standard oncology survivorship care.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Recruitment Rate
Délai: From start to end of recruitment, up to 6 months

Number of participants randomised per site per month. Progression target: at least 4 participants per site per month.

From start to end of recruitment, up to 6 months
Retention
Délai: 3 months after the end of the intervention

Percentage of randomised participants who complete the 3-month follow-up questionnaires. Progression target: at least 80%.

3 months after the end of the intervention
Session Attendance
Délai: During the 8-week intervention

Percentage of the 8 intervention sessions attended by participants in the BRIGHT arm, from attendance records. Progression target: at least 75% session completion.

During the 8-week intervention
Intervention Fidelity
Délai: During the 8-week intervention

Percentage of planned session components delivered as intended, assessed using facilitator session checklists and independent review of a sample of recorded sessions. Progression target: at least 85%.

During the 8-week intervention
Acceptability
Délai: Week 8 (end of the intervention)

Participant satisfaction with the intervention, measured using a questionnaire based on the Theoretical Framework of Acceptability, and explored in interviews with 15 to 20 participants and facilitators.

Week 8 (end of the intervention)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Depressive Symptoms
Délai: Baseline, Week 8 and 3 months after the end of the intervention

Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27; higher scores mean more severe depressive symptoms.

Baseline, Week 8 and 3 months after the end of the intervention
Anxiety Symptoms
Délai: Baseline, Week 8 and 3 months after the end of the intervention

Generalised Anxiety Disorder-7 (GAD-7). Scores range from 0 to 21; higher scores mean more severe anxiety.

Baseline, Week 8 and 3 months after the end of the intervention
Fear of Cancer Recurrence
Délai: Baseline, Week 8 and 3 months after the end of the intervention

Fear of Cancer Recurrence Inventory, Short Form (FCRI-SF). Scores range from 0 to 36; higher scores mean greater fear of recurrence.

Baseline, Week 8 and 3 months after the end of the intervention
Cancer-Specific Quality of Life
Délai: Baseline, Week 8 and 3 months after the end of the intervention

Functional Assessment of Cancer Therapy, Breast (FACT-B). Total scores range from 0 to 148; higher scores mean better quality of life.

Baseline, Week 8 and 3 months after the end of the intervention
Psychological Resilience
Délai: Baseline, Week 8 and 3 months after the end of the intervention

Connor-Davidson Resilience Scale (CD-RISC). Higher scores mean greater resilience

Baseline, Week 8 and 3 months after the end of the intervention
Unmet Supportive Care Needs
Délai: Baseline, Week 8 and 3 months after the end of the intervention

Supportive Care Needs Survey, Short Form (SCNS-SF34). Domain scores range from 0 to 100; higher scores mean greater unmet need.

Baseline, Week 8 and 3 months after the end of the intervention

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Collaborateurs

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 octobre 2029

Achèvement primaire (Estimé)

1 septembre 2030

Achèvement de l'étude (Estimé)

1 septembre 2030

Dates d'inscription aux études

Première soumission

5 novembre 2026

Première soumission répondant aux critères de contrôle qualité

5 novembre 2026

Première publication (Réel)

12 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Description du régime IPD

A decision on sharing anonymised individual participant data will be made before recruitment starts, in line with University College Dublin policy, funder requirements and GDPR.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner